Walser Wealth Management’s AbbVie ABBV Stock Holding History

Walser Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$512K	Buy	2,033 +487	+32%	+$105K	0.21%	112
2026 Q1	$336K	Buy	+1,546	New	+$343K	0.15%	115

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Walser Wealth Management's ABBV Position: Q2 2026 in Review

Walser Wealth Management increased its AbbVie (ABBV) stake by 32% in Q2 2026, buying an estimated $105K and bringing the position to 2,033 shares worth $512K. The position accounts for 0.21% of the portfolio, ranked #112.

Walser Wealth Management first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Walser Wealth Management held 2,033 shares of AbbVie worth $512K as of Q2 2026.
Walser Wealth Management bought 487 AbbVie shares in Q2 2026, an estimated $105K.
AbbVie made up 0.21% of Walser Wealth Management's portfolio in Q2 2026, its #112 holding.
Walser Wealth Management first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Walser Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.